Objectives: The industry perspective on drug costs should be framed by the need for decision-makers to use actual and relevant costs, and to inform real-world decisions regarding medication selection and use. The objective of this report is to provide guidance and recommendations on how manufacturers should approach the use of drug costs.

Methods: The Task Force was appointed with the advice and consent of the ISPOR Board of Directors. Members were experienced developers or users of drug cost information working in academia and industry, and came from several countries. Following the core assumptions developed and outlined by the Task Force, a draft report was prepared. Comments were solicited on the outline and several draft reports both from a core group of external reviewers and more broadly from the ISPOR membership of ISPOR via the ISPOR Web site.

Results: The industry should always strive for: 1) a focus on drug value and not just cost; 2) credibility-that is correct and consistent costs; 3) transparency-by disclosing the prices and costs, and ensuring that they reflect the actual cost of the drug whenever possible; and 4) providing actionable results that help customers comprehend the value offered by a drug therapy and to use products more efficiently and effectively.

Conclusions: Understanding and accounting for all costs and consequences of the use of a medical treatment is in the best interests of all parties involved in the prescribing, consuming, reimbursement, selling, and manufacturing of bio/pharmaceuticals. Transparency, consistency, and clear communication of costs and value are essential for appropriate decision-making and should be important goals for all parties.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1524-4733.2009.00664.xDOI Listing

Publication Analysis

Top Keywords

drug cost
12
task force
12
drug
8
drug costs
8
industry perspective
8
costs
7
cost
5
ispor
5
good practices
4
practices measuring
4

Similar Publications

Cardiovascular diseases (CVDs) are the leading cause of mortality and morbidity globally. It is estimated that 17.9 million people died from CVDs in 2019, which represents 32 % of all deaths worldwide.

View Article and Find Full Text PDF

Sulfilimines from a Medicinal Chemist's Perspective: Physicochemical and in Vitro Parameters Relevant for Drug Discovery.

J Med Chem

January 2025

Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Straße 65, 88397 Biberach an der Riß, Germany.

While sulfoximines are nowadays a well established functional group for medicinal chemistry, the properties of sulfilimines are significantly less well studied, and no sulfilimine has progressed to the clinic to date. In this account, the physicochemical and in vitro properties of sulfilimines are reported and compared to those of sulfoximines and other more traditional functional groups. Furthermore, the impact on the physicochemical and in vitro properties of real drug scaffolds is studied in two series of sulfilimine-containing analogs of imatinib and hNE inhibitors.

View Article and Find Full Text PDF

Digital twins, driven by data and mathematical modelling, have emerged as powerful tools for simulating complex biological systems. In this work, we focus on modelling the clearance on a liver-on-chip as a digital twin that closely mimics the clearance functionality of the human liver. Our approach involves the creation of a compartmental physiological model of the liver using ordinary differential equations (ODEs) to estimate pharmacokinetic (PK) parameters related to on-chip liver clearance.

View Article and Find Full Text PDF

Importance: Medication adherence is important for managing blood pressure (BP), low-density lipoprotein cholesterol (LDL-C), and hemoglobin A1c (HbA1c). Interventions to improve medication adherence are needed.

Objective: To examine the effectiveness of an intervention using algorithmic identification of low medication adherence, clinical decision support to physicians, and pharmacist outreach to patients to improve cardiometabolic medication adherence and BP, LDL-C, and HbA1c control.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

RxY, New York, NY, USA.

Background: Disease-modifying therapies (DMTs) such as lecanemab and aducanumab are recommended for the treatment of patients with confirmed Alzheimer's disease (AD) within the mild cognitive impairment (MCI) or mild stages of dementia. Biomarker testing is required to confirm the presence of amyloid beta for prescription of DMTs. Confirmatory diagnosis at the MCI stage is important to take advantage of the narrow treatment window of currently available DMTs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!